As most DCIS cases are estrogen receptor-positive with tamoxifen being a therapeutic option, COL11A1-estrogen receptor interactions need to be investigated as a potential mechanism of therapeutic resistance and recurrence. This evidence concerns the gene COL11A1 and ductal breast carcinoma in situ.